450 related articles for article (PubMed ID: 27765068)
21. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.
Balch C; Yan P; Craft T; Young S; Skalnik DG; Huang TH; Nephew KP
Mol Cancer Ther; 2005 Oct; 4(10):1505-14. PubMed ID: 16227399
[TBL] [Abstract][Full Text] [Related]
22. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
23. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
[TBL] [Abstract][Full Text] [Related]
24. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Wang Z; Li M; Lu S; Zhang Y; Wang H
Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
[TBL] [Abstract][Full Text] [Related]
25. [Disfigurement of p16INK4A gene expression in development of ovarian cancer and the mechanism].
Li M; Huang ZJ; Dong WH; Li XY; Wang XY; He XH; Wang H; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):408-12. PubMed ID: 16831366
[TBL] [Abstract][Full Text] [Related]
26. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Kondrashova O; Topp M; Nesic K; Lieschke E; Ho GY; Harrell MI; Zapparoli GV; Hadley A; Holian R; Boehm E; Heong V; Sanij E; Pearson RB; Krais JJ; Johnson N; McNally O; Ananda S; Alsop K; Hutt KJ; Kaufmann SH; Lin KK; Harding TC; Traficante N; ; deFazio A; McNeish IA; Bowtell DD; Swisher EM; Dobrovic A; Wakefield MJ; Scott CL
Nat Commun; 2018 Sep; 9(1):3970. PubMed ID: 30266954
[TBL] [Abstract][Full Text] [Related]
27. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
[TBL] [Abstract][Full Text] [Related]
28. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
Tellez CS; Grimes MJ; Picchi MA; Liu Y; March TH; Reed MD; Oganesian A; Taverna P; Belinsky SA
Int J Cancer; 2014 Nov; 135(9):2223-31. PubMed ID: 24668305
[TBL] [Abstract][Full Text] [Related]
29. Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile.
Khamas A; Ishikawa T; Shimokawa K; Mogushi K; Iida S; Ishiguro M; Mizushima H; Tanaka H; Uetake H; Sugihara K
Cancer Genomics Proteomics; 2012; 9(2):67-75. PubMed ID: 22399497
[TBL] [Abstract][Full Text] [Related]
30. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma.
Nestheide S; Bridge JA; Barnes M; Frayer R; Sumegi J
Pediatr Blood Cancer; 2013 Sep; 60(9):1437-46. PubMed ID: 23508900
[TBL] [Abstract][Full Text] [Related]
33. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.
Topp MD; Hartley L; Cook M; Heong V; Boehm E; McShane L; Pyman J; McNally O; Ananda S; Harrell M; Etemadmoghadam D; Galletta L; Alsop K; Mitchell G; Fox SB; Kerr JB; Hutt KJ; Kaufmann SH; Australian Ovarian Cancer Study ; Swisher EM; Bowtell DD; Wakefield MJ; Scott CL
Mol Oncol; 2014 May; 8(3):656-68. PubMed ID: 24560445
[TBL] [Abstract][Full Text] [Related]
34. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Wang BL; Chen L; Yang WT; Shen ZZ; Huang W; Shao ZM
Hum Pathol; 2010 Jan; 41(1):48-58. PubMed ID: 19733895
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
Tucker DW; Getchell CR; McCarthy ET; Ohman AW; Sasamoto N; Xu S; Ko JY; Gupta M; Shafrir A; Medina JE; Lee JJ; MacDonald LA; Malik A; Hasselblatt KT; Li W; Zhang H; Kaplan SJ; Murphy GF; Hirsch MS; Liu JF; Matulonis UA; Terry KL; Lian CG; Dinulescu DM
Clin Cancer Res; 2018 Mar; 24(6):1389-1401. PubMed ID: 29263182
[No Abstract] [Full Text] [Related]
36. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
[TBL] [Abstract][Full Text] [Related]
37. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
38. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
[TBL] [Abstract][Full Text] [Related]
39. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines.
Schaefer M; Hagemann S; Hanna K; Lyko F
Cancer Res; 2009 Oct; 69(20):8127-32. PubMed ID: 19808971
[TBL] [Abstract][Full Text] [Related]
40. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
